MiNK Therapeutics (NASDAQ:INKT) Trading Up 2.5% – Should You Buy?

MiNK Therapeutics, Inc. (NASDAQ:INKT)’s share price shot up 2.5% during trading on Tuesday . The stock traded as high as $7.83 and last traded at $7.75. 2,436 shares traded hands during trading, a decline of 83% from the average session volume of 14,604 shares. The stock had previously closed at $7.56.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of MiNK Therapeutics in a report on Tuesday, March 18th.

MiNK Therapeutics Stock Performance

The company has a market cap of $30.26 million, a PE ratio of -1.96 and a beta of 0.15. The business’s 50-day moving average is $8.69 and its 200 day moving average is $7.84.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Tuesday, March 18th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12). Equities research analysts anticipate that MiNK Therapeutics, Inc. will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.